228 related articles for article (PubMed ID: 26715450)
1. MDR-1 and MRP-1 activity in peripheral blood leukocytes of rheumatoid arthritis patients.
Micsik T; Lőrincz A; Gál J; Schwab R; Peták I
Diagn Pathol; 2015 Dec; 10():216. PubMed ID: 26715450
[TBL] [Abstract][Full Text] [Related]
2. Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug.
Hider SL; Owen A; Hartkoorn R; Khoo S; Back D; Silman AJ; Bruce IN
Ann Rheum Dis; 2006 Oct; 65(10):1390-3. PubMed ID: 16504991
[TBL] [Abstract][Full Text] [Related]
3. Differential effect of methotrexate on the increased CCR2 density on circulating CD4 T lymphocytes and monocytes in active chronic rheumatoid arthritis, with a down regulation only on monocytes in responders.
Ellingsen T; Hornung N; Møller BK; Poulsen JH; Stengaard-Pedersen K
Ann Rheum Dis; 2007 Feb; 66(2):151-7. PubMed ID: 16905577
[TBL] [Abstract][Full Text] [Related]
4. CD39 positive regulatory T cell frequency as a biomarker of treatment response to methotrexate in rheumatoid arthritis.
Gupta V; Katiyar S; Singh A; Misra R; Aggarwal A
Int J Rheum Dis; 2018 Aug; 21(8):1548-1556. PubMed ID: 30146748
[TBL] [Abstract][Full Text] [Related]
5. High serum level of haptoglobin is associated with the response of 12 weeks methotrexate therapy in recent-onset rheumatoid arthritis patients.
Tan W; Wang F; Guo D; Ke Y; Shen Y; Lv C; Zhang M
Int J Rheum Dis; 2016 May; 19(5):482-9. PubMed ID: 24863583
[TBL] [Abstract][Full Text] [Related]
6. Multidrug resistance protein-1 expression, function and polymorphisms in patients with rheumatoid arthritis not responding to methotrexate.
Prasad S; Tripathi D; Rai MK; Aggarwal S; Mittal B; Agarwal V
Int J Rheum Dis; 2014 Nov; 17(8):878-86. PubMed ID: 24734954
[TBL] [Abstract][Full Text] [Related]
7. The dimeric form of HLA-G molecule is associated with the response of early rheumatoid arthritis (ERA) patients to methotrexate.
Rizzo R; Farina I; Bortolotti D; Galuppi E; Padovan M; Di Luca D; Govoni M
Clin Rheumatol; 2017 Mar; 36(3):701-705. PubMed ID: 27778096
[TBL] [Abstract][Full Text] [Related]
8. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
Rau R; Schleusser B; Herborn G; Karger T
J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
[TBL] [Abstract][Full Text] [Related]
9. Increased baseline RUNX2, caspase 3 and p21 gene expressions in the peripheral blood of disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients are associated with improved clinical response to methotrexate therapy.
Tchetina EV; Demidova NV; Markova GA; Taskina EA; Glukhova SI; Karateev DE
Int J Rheum Dis; 2017 Oct; 20(10):1468-1480. PubMed ID: 28741869
[TBL] [Abstract][Full Text] [Related]
10. In active chronic rheumatoid arthritis, dipeptidyl peptidase IV density is increased on monocytes and CD4(+) T lymphocytes.
Ellingsen T; Hornung N; Møller BK; Hjelm-Poulsen J; Stengaard-Pedersen K
Scand J Immunol; 2007 Oct; 66(4):451-7. PubMed ID: 17850590
[TBL] [Abstract][Full Text] [Related]
11. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
[TBL] [Abstract][Full Text] [Related]
12. Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide.
van der Heijden JW; Oerlemans R; Tak PP; Assaraf YG; Kraan MC; Scheffer GL; van der Laken CJ; Lems WF; Scheper RJ; Dijkmans BA; Jansen G
Arthritis Rheum; 2009 Mar; 60(3):669-77. PubMed ID: 19248091
[TBL] [Abstract][Full Text] [Related]
13. Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients.
Samara SA; Irshaid YM; Mustafa KN
Int J Clin Pharmacol Ther; 2014 Sep; 52(9):746-55. PubMed ID: 25074866
[TBL] [Abstract][Full Text] [Related]
14. Predicting methotrexate resistance in rheumatoid arthritis patients.
Yu MB; Firek A; Langridge WHR
Inflammopharmacology; 2018 Jun; 26(3):699-708. PubMed ID: 29532212
[TBL] [Abstract][Full Text] [Related]
15. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Van der Elst K; Meyfroidt S; Westhovens R;
Arthritis Res Ther; 2015 Apr; 17(1):97. PubMed ID: 25889222
[TBL] [Abstract][Full Text] [Related]
16. Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis.
Murota A; Suzuki K; Kassai Y; Miyazaki T; Morita R; Kondo Y; Takeshita M; Niki Y; Yoshimura A; Takeuchi T
Cytokine; 2016 Feb; 78():87-93. PubMed ID: 26700586
[TBL] [Abstract][Full Text] [Related]
17. Peripheral Lymphocyte Multidrug Resistance Activity as a Predictive Tool of Biological Therapeutic Response in Rheumatoid Arthritis.
Toldi G; Batel P; Baráth S; Szerémy P; Apjok A; Filkor K; Szántó S; Szűcs G; Szamosi S; Häupl T; Grützkau A; Szekanecz Z
J Rheumatol; 2019 Jun; 46(6):572-578. PubMed ID: 30709954
[TBL] [Abstract][Full Text] [Related]
18. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone.
O'Dell JR; Elliott JR; Mallek JA; Mikuls TR; Weaver CA; Glickstein S; Blakely KM; Hausch R; Leff RD
Arthritis Rheum; 2006 Feb; 54(2):621-7. PubMed ID: 16447240
[TBL] [Abstract][Full Text] [Related]
19. Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study).
van Aken J; Heimans L; Gillet-van Dongen H; Visser K; Ronday HK; Speyer I; Peeters AJ; Huizinga TW; Allaart CF
Ann Rheum Dis; 2014 Feb; 73(2):396-400. PubMed ID: 23334213
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
Seitz M; Zwicker M; Villiger PM
J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
